Article Sidebar

PDF (Tiếng Việt)
Published: 2022-10-06
Abstract Views: 162
Views PDF (Tiếng Việt): 649
DOI: https://doi.org/10.52852/tcncyh.v157i9.1047
Issue
Vol. 157 No. 9 (2022)
Section
Các bài báo
How to Cite
Hường, N. T. T. ., & Quảng, L. V. . (2022). 7. The prognostic role of Child-Pugh score in hepatocellular carcinoma patients treated with Sorafenib. Journal of Medical Research, 157(9), 55-62. https://doi.org/10.52852/tcncyh.v157i9.1047

7. The prognostic role of Child-Pugh score in hepatocellular carcinoma patients treated with Sorafenib

Nguyen Thi Thu Huong, Le Van Quang

Main Article Content

Abstract

Sorafenib has been approved for treatment of advanced hepatocellular carcinoma (HCC) since 2009; however, there were few studies evaluating prognostic factors in patients treated with this drug, including the severity of cirrhosis according to Child-Pugh in Vietnam. We conducted a descriptive study in 110 HCC patients treated at National Cancer Hospital and Hanoi Medical University Hospital from January 2010 to December 2018, in order to evaluate the role of Child-Pugh score to sorafenib treatment. The proportion of Child-Pugh A and B patients were 90.1% and 9.9%. The results between the two groups of CP A compared with CP B are as follows: the disease control rate was 60.6% vs 45.5% (p = 0.352), the median PFS was 4.7 months vs 2.9 months (p = 0.097); the median OS was 8.7 months vs 2.7 months (p < 0.001). The median OS of CP score was 5, 6, 7 and ≥ 8 points, and 10.6 months, 3.4 months, 5.9 months and 1.8 months (p < 0.001). Multivariate analysis showed that overall survival of CP A patients was 2.805 times longer than that of CP B patients (HR = 2.805, 95%CI: 1.250 - 6.290, p = 0.012). We concluded that Child-Pugh score was an independent predictor of the overall survival.

Article Details

Keywords

hepatocellular carcinoma, Sorafenib, Child-Pugh score

References

1. Cheng A L, Kang Y K, Chen Z , et al. Efficacy and safety of Sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10(1):25-34.
2. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. New England Journal of Medicine. 2008;359(4):378-390.
3. Jorge A Marrero, Masatoshi Kudo, Alan P Venook. Observational registry of Sorafenib use in clinical practice across Child-Pugh subgroups: The GIDEON study. Journal of hepatology. 2016;Vol.65:p1140-1147.
4. Nguyễn Tuyết Mai. Bước đầu đánh giá hiệu quả Sorafenib (Nexavar) trong điều trị ung thư gan nguyên phát giai đoạn muộn. Tạp chí Y học Việt Nam. 2012;1:34-37.
5. Vũ Thanh Tú. Nhận xét đặc điểm lâm sàng, cận lâm sàng và kết quả điều trị ung thư gan giai đoạn muộn bằng Sorafenib. Luận văn thạc sĩ Y học. Trường Đại học Y Hà Nội. 2013.
6. Võ Văn Kha. Đánh giá kết quả điều trị ung thư tế bào gan nguyên phát giai đoạn tiến xa bằng Sorafenib. Tạp chí Y dược lâm sàng. 2016;108(11):133-142.
7. Bộ Y tế Việt Nam. Hướng dẫn chẩn đoán và điều trị ung thư tế bào gan nguyên phát. Quyết định số 5250/QĐ-BYT. 2012.
8. National Cancer Institute. Common terminology criteria for adverse events (CTCAE). CTEP. Updated April 19, 2021. 196. https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm.
9. Hiraoka A, Kumada T, Kudo M et al. Albumin-Bilirubin (ALBI) grade as part of the evidence-based clinical practice guideline for HCC of the Japan Society of Hepatology: A comparison with the liver damage and Child-Pugh classifications. Liver Cancer. 2017;6(3):204-215.
10. Oikawa T, Sawara K, Kuroda H, et al. Sorafenib treatment for advanced hepatocellular carcinoma: Effectiveness, safety, and controversial points. JCO. 2017;35(4):496-496.
11. Leonardo GF, Romualdo BS, Afonso SA. Safety and efficacy of Sorafenib in patients with advanced hepatocellular carcinoma and Child-Pugh A or B cirrhosis. Molecular and Clinical Oncology. 2015;3(4):793-796.